SXTC
NASDAQChina SXT Pharmaceuticals
$2.83
+1.58 (+126.40%)
2026-10-07 00:00
Healthcare
Drug Manufacturers - Specialty & Generic
--
--
Short Interest (1 Year)
% of Volume Sold ShortMarket Cap
$3.7M
P/E Ratio
N/A
52W Low
52W High
$0.03
$9.59
Volume
144.8M
About China SXT Pharmaceuticals
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers Advanced TCMP, including Directly-Oral-TCMP, and After-Soaking-Oral TCMP; Fine TCMP and Regular TCMP products; and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXia...
Employees
56
Website
sxtchina.com
Financial Highlights
Annual
Quarterly
| Year | Revenue | Op Margin | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2026 | $1.1M | -664.1% | -$6.2M | -$4.0M |
| 2025 | $1.7M | -154.0% | -$3.3M | -$2.3M |
| 2024 | $1.9M | -130.4% | -$3.1M | -$1.9M |
| 2023 | $2.0M | -284.4% | -$5.9M | -$10K |
| 2022 | $2.6M | -199.4% | -$5.7M | -$2.3M |
| 2026 Q2 | $1.2M | -65.4% | $164K | -$2.3M |
| 2025 Q4 | $256K | -153.3% | $82K | -$1.1M |
| 2025 Q3 | $627K | -1011.7% | -$6.4M | -$1.8M |
| 2025 Q2 | $456K | -224.1% | -$1.3M | N/A |
| 2025 Q1 | N/A | N/A% | N/A | N/A |
| 2024 Q4 | $456K | -224.1% | -$1.3M | -$719K |
| 2024 Q2 | $415K | -76.9% | -$401K | -$661K |
| 2024 Q1 | N/A | N/A% | N/A | N/A |